CRS-207 is engineered to express mesothelin, which is expressed in pancreatic cancer, mesothelioma and other cancers.
Aduro to Present Pancreatic Cancer and Mesothelioma Abstracts at 2014 ASCO Annual Meeting
CRS-207 is engineered to express mesothelin, which is expressed in pancreatic cancer, mesothelioma and other cancers.